Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

September 1, 2020

Study Completion Date

August 3, 2022

Conditions
Chronic Lymphocytic Leukemia (CLL)Waldenstrom Macroglobulinemia (WM)
Interventions
DRUG

Shingrix vaccine

On day one, patients will receive the first of two doses of the Shingrix vaccine administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.

Trial Locations (1)

14623

University of Rochester, Rochester

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Rochester

OTHER